BIVI Stock Price, BioVie Inc. Quote, Chart

Market Summary

USD0.490.00

Market Closed

0.00%

BIVI Stock Price

View Fullscreen

BIVI RSI Chart

BIVI Valuation

Market Cap

19.5M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

24.59

Price/Free Cashflow

-0.48

BIVI Price/Sales (Trailing)

BIVI Profitability

Return on Equity

-577.54%

Return on Assets

-201.32%

Free Cashflow Yield

-210.42%

BIVI Fundamentals

BIVI Revenue

Revenue (TTM)

794.4K

Rev. Growth (Yr)

161.84%

Rev. Growth (Qtr)

-52.83%

BIVI Earnings

Earnings (TTM)

-43.3M

Earnings Growth (Yr)

46.44%

Earnings Growth (Qtr)

21.56%

Breaking Down BIVI Revenue

Last 30 days

-7.5%

Last 90 days

-46.7%

Trailing 12 Months

-93.5%

How does BIVI drawdown profile look like?

BIVI Financial Health

Current Ratio

1.47

Debt/Equity

0.01

Debt/Cashflow

-691.35

BIVI Investor Care

Shares Dilution (1Y)

13.96%

Diluted EPS (TTM)

-1.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	152.8K	239.0K	659.7K	794.4K
2022	40.2K	44.1K	78.0K	149.6K
2021	0	22.0K	28.8K	35.6K
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioVie Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	do cuong v	bought	-	-	10,000	president & ceo
Dec 11, 2023	kim joanne wendy	acquired	-	-	5,000	chief financial officer
Dec 01, 2023	gorlin steve	sold	-127,899	1.69	-75,680	-
Nov 30, 2023	do cuong v	bought	17,800	1.78	10,000	president & ceo
Nov 09, 2023	rogich sigmund	acquired	-	-	42,254	-
Nov 09, 2023	hariri robert j	acquired	-	-	42,254	-
Nov 09, 2023	gorlin steve	acquired	-	-	46,358	-
Nov 09, 2023	berman richard j	acquired	-	-	51,830	-
Sep 05, 2023	gorlin steve	sold	-26,108	3.05	-8,560	-
Aug 22, 2023	berman richard j	sold	-37,827	3.5009	-10,805	-

Which funds bought or sold BIVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-2.09	-12,097	8,434	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-82.3	-18,000	1,000	-%
Apr 24, 2024	Spire Wealth Management	reduced	-0.27	-1,082	793	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	added	183	1,426	8,986	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.17	-1,000	-	-%
Apr 23, 2024	Summit Trail Advisors, LLC	unchanged	-	-7,387	5,339	-%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	-428	309	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	-36.00	27.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	76.09	-238,041	443,331	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	262	1,919	7,569	-%

Are Funds Buying or Selling BIVI?

Are funds buying BIVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIVI

No. of Funds

Unveiling BioVie Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 10, 2023	acuitas group holdings, llc	71.91%	30,435,738	SC 13D/A
Mar 07, 2023	acuitas group holdings, llc	87.0%	30,438,938	SC 13D/A
Aug 16, 2022	acuitas group holdings, llc	84.8%	30,438,938	SC 13D/A
Jul 15, 2022	acuitas group holdings, llc	78.2%	19,529,846	SC 13D/A
Jun 11, 2021	peizer terren s	87.5%	19,529,846	SC 13D/A
May 10, 2021	peizer terren s	80.0%	11,168,538	SC 13D/A
Apr 27, 2021	peizer terren s	80.0%	11,168,538	SC 13D/A
Sep 23, 2020	peizer terren s	80.3%	11,168,538	SC 13D/A

Recent SEC filings of BioVie Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 04, 2024	8-K/A	Current Report
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	424B5	Prospectus Filed
Mar 01, 2024	8-K	Current Report
Mar 01, 2024	424B5	Prospectus Filed
Feb 13, 2024	10-Q	Quarterly Report

Peers (Alternatives to BioVie Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

BioVie Inc. News

Latest updates

BioVie Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2	2019Q1	2019Q1	2018Q3
Revenue	-52.8%	218	462	98.00	17.00	83.00	42.00	11.00	13.00	12.00	8.00	8.00	9.00	1,340	2,671	4,002	5,334	6,665	-	-	-	-
Operating Expenses	-19.3%	8,781	10,876	10,977	13,775	11,495	8,834	9,292	5,749	6,665	5,547	131,603	3,002	3,063	387	577	699	710	656	848	-	491
S&GA Expenses	16.0%	2,254	1,943	2,620	2,520	4,405	2,007	3,362	2,114	1,894	2,395	282	2,155	2,068	228	391	289	307	323	459	-	240
R&D Expenses	-27.1%	6,470	8,876	8,300	11,197	7,033	6,770	5,873	3,577	4,714	3,095	621	790	938	101	128	353	347	276	332	-	195
Interest Expenses	-18.3%	821	1,005	1,108	1,083	1,053	1,056	927	919	316	1.00	-	-	143*	559	1,240	34.00	21.00	1*	1*	-	272*
Net Income	21.6%	-8,401	-10,710	-9,111	-15,041	-15,687	-10,415	-8,088	-7,040	-5,414	-5,540	-131,532	-2,992	-3,057	7,334	-19,154	-366	6,665	-655	-848	-	-439
Net Income Margin	28.9%	-54.46*	-76.63*	-210.26*	-322.16*	-275.64*	-396.82*	-591.76*	-3.72	-4.09	-4.98	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	51.5%	-5,909	-12,177	-11,287	-11,735	-8,009	-9,220	-5,865	-5,884	-4,706	-2,534	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q2	2019Q1
Assets	-9.6%	21.00	24.00	35.00	45.00	47.00	23.00	20.00	26.00	32.00	22.00	6.00	13.00	13.00	15.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00
Current Assets	-9.7%	21.00	23.00	34.00	44.00	46.00	22.00	19.00	25.00	31.00	21.00	5.00	11.00	12.00	13.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
Cash Equivalents	-4.7%	20.00	21.00	19.00	31.00	46.00	21.00	19.00	25.00	30.00	20.00	5.00	11.00	0.00	13.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-13.7%	14.00	16.00	20.00	23.00	21.00	17.00	16.00	16.00	16.00	2.00	1.00	1.00	9.00	16.00	24.00	5.00	4.00	11.00	0.00	0.00	0.00
Current Liabilities	5.8%	14.00	13.00	14.00	16.00	8.00	4.00	4.00	4.00	4.00	1.00	1.00	1.00	0.00	0.00	24.00	5.00	4.00	11.00	0.00	0.00	0.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Shareholder's Equity	-0.8%	7.00	8.00	15.00	22.00	26.00	6.00	4.00	10.00	16.00	20.00	5.00	11.00	13.00	15.00	-	-	-	-	2.00	3.00	3.00
Retained Earnings	-2.7%	-320	-311	-301	-292	-277	-261	-250	-242	-235	-230	-224	-93.35	-90.36	-87.30	-41.04	-21.88	-21.52	-28.18	-7.26	-6.61	-6.61
Additional Paid-In Capital	2.6%	328	319	316	314	303	267	255	253	252	251	230	105	103	102	20.00	20.00	19.00	19.00	9.00	9.00	9.00
Shares Outstanding	8.0%	40.00	37.00	36.00	36.00	31.00	27.00	25.00	25.00	25.00	24.00	22.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	86.00	-	-	-	23.00	-	-	-	18.00	-	18.00	-	-	-	53.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	51.5%	-5,909	-12,177	-11,287	-11,735	-8,009	-9,220	-5,865	-5,884	-4,706	-2,534	-7,008	-1,041	-1,319	-1,083	-360	-401	-275	-590	-631	-658	-769
Share Based Compensation	-100.0%	-	808	742	18.00	18.00	879	1,803	930	1,147	1,927	679	804	1,537	-	-	14.00	11.00	-	2.00	44.00	16.00
Cashflow From Investing	-100.0%	-	14,525	-1,796	-12,504	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	928.4%	4,922	-594	1,268	9,768	32,527	11,810	-	-	14,610	18,511	169	517	-	14,242	394	402	30.00	500	-	-	264

BIVI Income Statement

2023-12-31

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES:
Amortization	$ 57,344	$ 57,344	$ 114,688	$ 114,688
Research and development expenses	6,470,262	7,032,898	15,345,922	13,802,830
Selling, general and administrative expenses	2,253,802	4,404,564	4,196,619	6,411,626
TOTAL OPERATING EXPENSES	8,781,408	11,494,806	19,657,229	20,329,144
LOSS FROM OPERATIONS	(8,781,408)	(11,494,806)	(19,657,229)	(20,329,144)
OTHER (INCOME) EXPENSE:
Change in fair value of derivative liabilities	(982,534)	3,222,010	(1,690,336)	3,788,552
Interest expense	820,600	1,053,455	1,825,268	2,109,871
Interest income	(218,029)	(83,269)	(680,252)	(124,854)
TOTAL OTHER (INCOME) EXPENSE, NET	(379,963)	4,192,196	(545,320)	5,773,569
NET LOSS	(8,401,445)	(15,687,002)	(19,111,909)	(26,102,713)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (8,401,445)	$ (15,687,002)	$ (19,111,909)	$ (26,102,713)
NET LOSS PER COMMON SHARE
- Basic	$ (0.22)	$ (0.50)	$ (0.51)	$ (0.89)
- Diluted	$ (0.22)	$ (0.50)	$ (0.51)	$ (0.89)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
- Basic	38,170,766	31,168,826	37,444,764	29,201,445
- Diluted	38,170,766	31,168,826	37,444,764	29,201,445
NET LOSS	$ (8,401,445)	$ (15,687,002)	$ (19,111,909)	$ (26,102,713)
Other comprehensive loss
Reclassification of unrealized gains on available-for-sale investments upon settlement			(176,591)
Total other comprehensive loss			(176,591)
Comprehensive loss	$ (8,401,445)	$ (15,687,002)	$ (19,288,500)	$ (26,102,713)

BIVI Balance Sheet

2023-12-31

Condensed Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 20,226,698	$ 19,460,883
Investments in U.S. Treasury Bills		14,477,726
Prepaids and other current assets	334,963	102,526
Total current assets	20,561,661	34,041,135
Operating lease right-of-use assets, net	60,418	80,789
Intangible assets, net	522,407	637,095
Goodwill	345,711	345,711
TOTAL ASSETS	21,490,197	35,104,730
CURRENT LIABILITIES:
Accounts payable and accrued expenses	3,608,096	3,476,259
Other current liabilities		48,385
Current portion of operating lease liabilities	48,231	44,909
Current portion of note payable, net of financing cost, unearned premium and discount of $195,325 at December 31, 2023 and $894,926 at June 30, 2023	10,195,325	9,105,074
Warrant liabilities	123,158	894,280
Embedded derivative liability	6,548	925,762
Total current liabilities	13,981,358	14,494,669
Operating lease liabilities, net of current portion	17,604	42,505
Note payable, net of current portion, financing cost, unearned premium and discount of $0 and $227,270 at December 31, 2023 and June 30, 2023, respectively.		5,227,270
TOTAL LIABILITIES	13,998,962	19,764,444
STOCKHOLDERS' EQUITY :
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2023 and June 30, 2023, respectively; 39,866,714 shares issued of which 39,843,834 shares are outstanding at December 31, 2023; and 36,451,829 shares issued of which 36,428,949 shares outstanding at June 30, 2023;	3,984	3,643
Additional paid in capital	327,824,867	316,385,759
Accumulated other comprehensive income		176,591
Accumulated deficit	(320,337,614)	(301,225,705)
Treasury stock	(2)	(2)
Total stockholders' equity	7,491,235	15,340,286
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 21,490,197	$ 35,104,730

About BioVie Inc.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

CEO	Mr. Cuong Viet Do M.B.A., MBA
WEBSITE	https://bioviepharma.com
INDUSTRY	Biotechnology
EMPLOYEES	18

BioVie Inc. Frequently Asked Questions

What is the ticker symbol for BioVie Inc.? What does BIVI stand for in stocks?

BIVI is the stock ticker symbol of BioVie Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioVie Inc. (BIVI)?

As of Fri Apr 26 2024, market cap of BioVie Inc. is 19.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIVI stock?

You can check BIVI's fair value in chart for subscribers.

What is the fair value of BIVI stock?

You can check BIVI's fair value in chart for subscribers. The fair value of BioVie Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioVie Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioVie Inc. a good stock to buy?

The fair value guage provides a quick view whether BIVI is over valued or under valued. Whether BioVie Inc. is cheap or expensive depends on the assumptions which impact BioVie Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIVI.

What is BioVie Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, BIVI's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 24.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIVI PE ratio will change depending on the future growth rate expectations of investors.